These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17257447)

  • 1. The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.
    Cremieux PY; Van Audenrode M; Lefebvre P
    Curr Med Res Opin; 2006 Dec; 22(12):2329-36. PubMed ID: 17257447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB
    J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.
    Vekeman F; McKenzie RS; Lefebvre P; Watson SH; Mody SH; Piech CT; Duh MS
    Am J Health Syst Pharm; 2007 Sep; 64(18):1943-9. PubMed ID: 17823106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darbepoetin for the anaemia of chronic kidney disease.
    Palmer SC; Saglimbene V; Craig JC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009297. PubMed ID: 24683046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study.
    Gobin J; Cernii A; McLean R; Finkelstein FO; Simon DB
    Clin Drug Investig; 2011; 31(2):113-20. PubMed ID: 21067252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.
    Kuwahara M; Hasumi S; Mandai S; Tanaka T; Shikuma S; Akita W; Mori Y; Sasaki S
    Clin Exp Nephrol; 2014 Oct; 18(5):755-62. PubMed ID: 24317507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios.
    Raymond CB; Wazny LD; Vercaigne LM; Lesperance EM; Skwarchuk DE; Bernstein KN
    CANNT J; 2008; 18(1):39-43. PubMed ID: 18435363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.
    Moyo V; Lefebvre P; Duh MS; Yektashenas B; Mundle S
    Ann Hematol; 2008 Jul; 87(7):527-36. PubMed ID: 18351340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting.
    Kruep EJ; Basskin LE
    Am J Health Syst Pharm; 2005 Dec; 62(24):2597-603. PubMed ID: 16333057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application.
    Cremieux P; Vekeman F; Lefebvre P
    J Oncol Pharm Pract; 2006 Sep; 12(3):165-78. PubMed ID: 17022871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification.
    Liao SC; Hung CC; Lee CT; Lee CH; Lee CC; Lin CL; Sun CY; Cheng BC; Yang CC; Wu CH; Chen JB
    Ther Apher Dial; 2016 Aug; 20(4):400-7. PubMed ID: 27060362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
    Sharma A; Yee J; Gandra SR; Khan I; Petersen J
    Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.